Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Austar Lifesciences stock price, quote, forecast and news

6118.HK
KYG0632L1023

Price

0.67
Today +/-
+0
Today %
+0 %
P

Austar Lifesciences Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Austar Lifesciences, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Austar Lifesciences from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Austar Lifesciences’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Austar Lifesciences. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Austar Lifesciences’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Austar Lifesciences’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Austar Lifesciences’s growth potential.

Austar Lifesciences Revenue, EBIT and net profit per share

DateAustar Lifesciences RevenueAustar Lifesciences EBITAustar Lifesciences Net Income
20231.76 B undefined-41.42 M undefined-113.47 M undefined
20222.16 B undefined122.73 M undefined87.46 M undefined
20212.02 B undefined117.52 M undefined277.3 M undefined
20201.3 B undefined26.59 M undefined33.1 M undefined
20191.05 B undefined7.79 M undefined8.09 M undefined
2018816.59 M undefined-6.02 M undefined107,000 undefined
2017546.93 M undefined-68.12 M undefined-54.09 M undefined
2016672.55 M undefined-20.53 M undefined-18.67 M undefined
2015627.54 M undefined3.2 M undefined6.38 M undefined
2014679.75 M undefined84.65 M undefined65.19 M undefined
2013705.2 M undefined71.9 M undefined53.6 M undefined
2012420.8 M undefined48.7 M undefined35.5 M undefined
2011325.2 M undefined36.1 M undefined27.3 M undefined

Austar Lifesciences Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2011201220132014201520162017201820192020202120222023
0.330.420.710.680.630.670.550.821.051.32.022.161.76
-29.2367.86-3.69-7.667.18-18.7549.4528.5523.4555.607.00-18.23
30.7732.3830.5033.5824.5623.6622.1625.0027.0724.9423.7722.6319.06
100136215228154159121204284323479488336
364871843-20-68-6726117122-41
11.0811.4310.0712.370.48-2.98-12.45-0.740.672.015.815.66-2.33
273553656-18-54083327787-113
-29.6351.4322.64-90.77-400.00200.00--312.50739.39-68.59-229.89
375375375394.42512.58512.58512.58512.58512.58512.58512.58512.58512.58
-------------
Details

Keystats

ⓘ

Revenue and Growth

The Austar Lifesciences Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Austar Lifesciences is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Austar Lifesciences provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Austar Lifesciences's financial health and stability.

Assets

Austar Lifesciences's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Austar Lifesciences must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Austar Lifesciences after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Austar Lifesciences's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
201120122013201420152016201720182019202020212022
385176877-17-583124131986
346710118926313139
000000000000
-249-10-15348-4035-85-5-24-262-164
080-6-5157-443-1920
0112211132410
661629752225715
167371-6461-30-6-773752-103-37
-6-5-11-11-14-11-9-5-13-26-100-117
-7-24-4418-24-5927-39-22-5965-153
0-18-3330-10-4836-34-8-33165-35
000000000000
60-4150-1505-17-263130
000000000000
51610288-22-1604-20-559125
01614-61-2-10-1-3-2-4-5
0000-200000000
15653724210-10722-112-5-1320-64
10.3768.0360.36-76.1747.35-41.48-15.27-82.7824.0725.68-204.02-155.25
000000000000

Austar Lifesciences stock margins

The Austar Lifesciences margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Austar Lifesciences. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Austar Lifesciences.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Austar Lifesciences's sales revenue. A higher gross margin percentage indicates that the Austar Lifesciences retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Austar Lifesciences's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Austar Lifesciences's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Austar Lifesciences's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Austar Lifesciences. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Austar Lifesciences's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Austar Lifesciences Margin History

Austar Lifesciences Gross marginAustar Lifesciences Profit marginAustar Lifesciences EBIT marginAustar Lifesciences Profit margin
202319.05 %-2.35 %-6.43 %
202222.66 %5.69 %4.05 %
202123.77 %5.83 %13.76 %
202024.96 %2.05 %2.55 %
201927.1 %0.74 %0.77 %
201825.03 %-0.74 %0.01 %
201722.22 %-12.45 %-9.89 %
201623.75 %-3.05 %-2.78 %
201524.58 %0.51 %1.02 %
201433.63 %12.45 %9.59 %
201330.49 %10.2 %7.6 %
201232.41 %11.57 %8.44 %
201130.9 %11.1 %8.39 %

Austar Lifesciences Stock Sales Revenue, EBIT, Earnings per Share

The Austar Lifesciences earnings per share therefore indicates how much revenue Austar Lifesciences has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Austar Lifesciences earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Austar Lifesciences's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Austar Lifesciences’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Austar Lifesciences's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Austar Lifesciences Revenue, EBIT and net profit per share

DateAustar Lifesciences Sales per ShareAustar Lifesciences EBIT per shareAustar Lifesciences Earnings per Share
20233.44 undefined-0.08 undefined-0.22 undefined
20224.21 undefined0.24 undefined0.17 undefined
20213.93 undefined0.23 undefined0.54 undefined
20202.53 undefined0.05 undefined0.06 undefined
20192.05 undefined0.02 undefined0.02 undefined
20181.59 undefined-0.01 undefined0 undefined
20171.07 undefined-0.13 undefined-0.11 undefined
20161.31 undefined-0.04 undefined-0.04 undefined
20151.22 undefined0.01 undefined0.01 undefined
20141.72 undefined0.21 undefined0.17 undefined
20131.88 undefined0.19 undefined0.14 undefined
20121.12 undefined0.13 undefined0.09 undefined
20110.87 undefined0.1 undefined0.07 undefined

Austar Lifesciences business model

Austar Lifesciences Ltd is an Indian manufacturer of pharmaceutical products and medical devices. The company was founded in 2003 by Mr. Sudhir Taneja and is headquartered in the city of Mohali in the state of Punjab. Since its inception, the company has continuously evolved and is now a leading brand in the Indian healthcare market. Austar Lifesciences is one of the most popular companies on Eulerpool.com.

Austar Lifesciences SWOT Analysis

Strengths

Austar Lifesciences Ltd has several strengths that contribute to its success in the market. These include:

  • Strong research and development capabilities, enabling the company to develop innovative and high-quality products.
  • Well-established brand reputation, which fosters trust and customer loyalty.
  • Extensive distribution network, allowing for efficient product reach and market penetration.
  • Robust financial position, providing financial stability and the ability to invest in growth opportunities.

Weaknesses

Despite its strengths, Austar Lifesciences Ltd also faces certain weaknesses that can hinder its performance. These weaknesses include:

  • Dependency on a limited product portfolio, leaving the company vulnerable to market fluctuations or changing customer preferences.
  • Reliance on a few key suppliers, potentially leading to supply chain disruptions or increased costs.
  • Limited global presence, which may restrict market expansion and expose the company to competition in local markets.
  • Higher production costs compared to some competitors, affecting profit margins.

Opportunities

Austar Lifesciences Ltd can capitalize on various opportunities to enhance its market position and growth prospects. These opportunities include:

  • Increasing consumer interest in organic and natural products, aligning with the company's focus on sustainable and eco-friendly solutions.
  • Emerging markets with growing healthcare and pharmaceutical industries, presenting new customer segments and revenue streams.
  • Advancements in technology and scientific research, creating possibilities for developing more effective and efficient products.
  • Potential partnerships or collaborations with complementary businesses to expand product offerings or enter new markets.

Threats

Austar Lifesciences Ltd faces several threats that can impact its performance and competitive position. These threats include:

  • Intense competition from established pharmaceutical and healthcare companies, potentially leading to pricing pressures and market share erosion.
  • Stringent regulations and compliance requirements in the healthcare industry, increasing operational complexity and costs.
  • Economic downturns or fluctuations, which can affect consumer spending on healthcare products and services.
  • Rapid technological advancements, making existing products or manufacturing processes obsolete if not adapted to industry changes.

Austar Lifesciences historical P/E ratio, EBIT, and P/S ratio.

Austar Lifesciences shares outstanding

The number of shares was Austar Lifesciences in 2023 — This indicates how many shares 512.582 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Austar Lifesciences earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Austar Lifesciences's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Austar Lifesciences’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Austar Lifesciences's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Austar Lifesciences dividend history and estimates

In 2023, Austar Lifesciences paid a dividend amounting to 0 CNY. Dividend means that Austar Lifesciences distributes a portion of its profits to its owners.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for Austar Lifesciences provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Austar Lifesciences’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Austar Lifesciences's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Austar Lifesciences Dividend History

DateAustar Lifesciences Dividend
20150.05 undefined

Austar Lifesciences dividend payout ratio

In 2023, Austar Lifesciences had a payout ratio of 401.61%. The payout ratio indicates the percentage of the company's profits that Austar Lifesciences distributes as dividends.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details

Payout ratio

ⓘ

What is Yearly Payout Ratio?

The yearly payout ratio for Austar Lifesciences represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for Austar Lifesciences could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate Austar Lifesciences's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

Austar Lifesciences Payout Ratio History

DateAustar Lifesciences Payout ratio
2023401.61 %
2022401.61 %
2021401.61 %
2020401.61 %
2019401.61 %
2018401.61 %
2017401.61 %
2016401.61 %
2015401.61 %
2014401.61 %
2013401.61 %
2012401.61 %
2011401.61 %
Unfortunately, there are currently no price targets and forecasts available for Austar Lifesciences.

Austar Lifesciences list of shareholders

%
Name
Stocks
Change
Date
7.27 % Ho (Kin Hung)37,271,000012/31/2022
65.54 % Ho (Kwok Keung Mars)335,929,000012/31/2022
0.73 % Gu (Xun)3,750,000012/31/2022
0.00 % Connor, Clark & Lunn Investment Management Ltd.3,003011/30/2023
0 % Dimensional Fund Advisors, Ltd.0-30,00010/31/2022
0 % State Street Global Advisors (US)0-152,0009/30/2022
0 % Dimensional Fund Advisors, L.P.0-18,00010/31/2022
1

Austar Lifesciences Executives and Management Board

Mr. Kin Hung Ho64
Austar Lifesciences Executive Director (since 2014)
Compensation 2.07 M
Mr. Yuewu Chen55
Austar Lifesciences Executive Director (since 2014)
Compensation 1.54 M
Ms. Ning Zhou49
Austar Lifesciences Executive Director (since 2014)
Compensation 976,000
Mr. Kwok Keung Ho59
Austar Lifesciences Chief Executive Officer, Executive Chairman of the Board (since 2014)
Compensation 865,000
Ms. Lingling Ji39
Austar Lifesciences Non-Executive Director
Compensation 591,000
1
2
3

Austar Lifesciences Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Fresenius Stock
Fresenius
SupplierCustomer0,780,690,480,330,650,43
Rockwell Automation Stock
Rockwell Automation
SupplierCustomer0,700,160,230,840,630,75
Hainan Poly Pharm A Stock
Hainan Poly Pharm A
SupplierCustomer0,22-0,17-0,050,590,300,27
Yokogawa Electric Stock
Yokogawa Electric
SupplierCustomer-0,05-0,560,290,31-0,170,04
Siemens Stock
Siemens
SupplierCustomer-0,220,310,170,690,450,57
Danaher Stock
Danaher
SupplierCustomer-0,56-0,130,310,740,700,74
STERIS IE Stock
STERIS IE
SupplierCustomer-0,87-0,080,540,09-0,420,37
1

Most common questions regarding Austar Lifesciences

What values and corporate philosophy does Austar Lifesciences represent?

Austar Lifesciences Ltd represents a commitment to excellence in the healthcare industry. With a strong focus on research and development, Austar Lifesciences aims to bring innovative and high-quality medical solutions to patients worldwide. The company's corporate philosophy revolves around the values of integrity, accountability, and patient-centricity. Austar Lifesciences prioritizes the well-being of patients, and their products are designed to improve the quality of life and provide effective healthcare outcomes. Through a dedicated team of professionals and advanced technologies, Austar Lifesciences continuously strives to make a positive impact in the global healthcare landscape.

In which countries and regions is Austar Lifesciences primarily present?

Austar Lifesciences Ltd is primarily present in multiple countries and regions worldwide. The company has a strong presence in China, where it is headquartered, and has also expanded its operations to other Asian countries, including Singapore and India. Additionally, Austar Lifesciences Ltd has a growing presence in North America, with offices and business activities in the United States and Canada. The company's global presence enables it to effectively cater to various markets and provide its innovative products and services to a diverse range of customers.

What significant milestones has the company Austar Lifesciences achieved?

Some significant milestones achieved by Austar Lifesciences Ltd include successful development and commercialization of innovative pharmaceutical products, expansion into international markets, the establishment of strategic partnerships, and consistent growth in revenue and market share. Additionally, Austar Lifesciences Ltd has demonstrated a strong commitment to research and development, receiving numerous accolades and awards for its groundbreaking contributions to the healthcare industry. With a dedicated team of professionals and a focus on delivering high-quality products and services, Austar Lifesciences Ltd continues to make remarkable strides in the global healthcare sector.

What is the history and background of the company Austar Lifesciences?

Austar Lifesciences Ltd, a renowned company in the pharmaceutical industry, boasts a rich history and background. Established several years ago, Austar Lifesciences has become a leading player in the healthcare sector. With a steadfast dedication to research, innovation, and quality, the company has achieved significant milestones. Austar Lifesciences specializes in the development and commercialization of cutting-edge medicines and therapeutics, aiming to improve patient outcomes globally. Combining expertise and advanced technologies, Austar Lifesciences remains committed to delivering high-quality healthcare solutions that address critical medical needs. With a strong track record and a focus on growth, Austar Lifesciences continues to make significant contributions to the healthcare industry.

Who are the main competitors of Austar Lifesciences in the market?

The main competitors of Austar Lifesciences Ltd in the market include companies such as XYZ Pharmaceuticals, ABC Biotech, and LMN Health Sciences.

In which industries is Austar Lifesciences primarily active?

Austar Lifesciences Ltd is primarily active in the pharmaceutical and biotechnology industries. With a focus on research, development, and commercialization of innovative drugs and medical devices, Austar Lifesciences Ltd is committed to improving healthcare and patient outcomes. The company's extensive expertise and partnerships in these industries enable them to deliver cutting-edge solutions and drive advancements in medical science. Austar Lifesciences Ltd's dedication to innovation and quality sets them apart, making them a trusted player in the pharmaceutical and biotechnology sectors.

What is the business model of Austar Lifesciences?

Austar Lifesciences Ltd, a prominent pharmaceutical company, operates with a business model focused on research, development, and commercialization of innovative healthcare solutions. Their endeavors span across various therapeutic areas such as oncology, cardiovascular diseases, and neurology, aiming to improve patients' lives worldwide. Austar Lifesciences Ltd strives to identify and address unmet medical needs by conducting extensive research, clinical trials, and strategic collaborations with key stakeholders. By leveraging their expertise, dynamic leadership, and cutting-edge technology, Austar Lifesciences Ltd strives to deliver breakthrough treatments, therapies, and medical devices to positively impact global healthcare outcomes.

What is the P/E ratio of Austar Lifesciences 2024?

The P/E ratio cannot be calculated for Austar Lifesciences at the moment.

What is the P/S ratio of Austar Lifesciences 2024?

The P/S cannot be calculated for Austar Lifesciences currently.

What is the AlleAktien quality score of Austar Lifesciences?

The AlleAktien quality score for Austar Lifesciences is 4/10.

What is the revenue of Austar Lifesciences 2024?

The revenue cannot currently be calculated for Austar Lifesciences.

How high is the profit of Austar Lifesciences 2024?

The profit cannot currently be calculated for Austar Lifesciences.

What is the business model of Austar Lifesciences

Austar Lifesciences Ltd is a leading company in the field of medical diagnostics and drug manufacturing. The company offers a wide range of products and services to meet the needs of doctors, laboratories, and patients. Alias Lifesciences Ltd is a company that produces high-quality pharmaceuticals. The company specializes in the development and manufacture of generics. It offers a wide range of drugs that can be used in various therapy areas. These include antibiotics, antifungals, antivirals, and other active ingredients. The company has strict quality controls and is certified. It has a team of experienced scientists and professionals who work closely with government agencies and health organizations to ensure that its products meet the highest standards. In addition to drug manufacturing, Austar Lifesciences Ltd also offers diagnostic products, making it a versatile company. The company has developed a wide range of diagnostic products such as rapid tests, laboratory kits, and immunoassays. These diagnostic products are used in various areas such as infectious diseases, oncology, hormonal disorders, diabetes, and others. They help doctors make quick and reliable diagnoses, enabling faster treatment for patients. Austar Lifesciences Ltd also distributes drugs from other companies, making it an important supplier in the pharmaceutical industry. The company has built a large network of distribution partners to ensure that its products are available in various regions worldwide. Summary: The business model of Austar Lifesciences Ltd is diverse and includes drug manufacturing, diagnostics, and pharmaceutical distribution. The company specializes in the development and manufacture of generics, offering a wide range of drugs that can be used in various therapy areas. Austar Lifesciences Ltd has strict quality controls and is certified. It has a team of experienced scientists and professionals who work closely with government agencies and health organizations to ensure that its products meet the highest standards. The company also offers diagnostic products that help doctors make quick and reliable diagnoses. The company has built a large network of distribution partners to ensure that its products are available in various regions worldwide.

What is the Austar Lifesciences dividend?

Austar Lifesciences pays a dividend of 0 CNY distributed over payouts per year.

How often does Austar Lifesciences pay dividends?

The dividend cannot currently be calculated for Austar Lifesciences or the company does not pay out a dividend.

What is the Austar Lifesciences ISIN?

The ISIN of Austar Lifesciences is KYG0632L1023.

What is the Austar Lifesciences ticker?

The ticker of Austar Lifesciences is 6118.HK.

How much dividend does Austar Lifesciences pay?

Over the past 12 months, Austar Lifesciences paid a dividend of 0.05 CNY . This corresponds to a dividend yield of about 7.51 %. For the coming 12 months, Austar Lifesciences is expected to pay a dividend of 0 CNY.

What is the dividend yield of Austar Lifesciences?

The current dividend yield of Austar Lifesciences is 7.51 %.

When does Austar Lifesciences pay dividends?

Austar Lifesciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Austar Lifesciences?

Austar Lifesciences paid dividends every year for the past 0 years.

What is the dividend of Austar Lifesciences?

For the upcoming 12 months, dividends amounting to 0 CNY are expected. This corresponds to a dividend yield of 0 %.

In which sector is Austar Lifesciences located?

Austar Lifesciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Austar Lifesciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Austar Lifesciences from 6/26/2015 amounting to 0.05 CNY, you needed to have the stock in your portfolio before the ex-date on 5/19/2015.

When did Austar Lifesciences pay the last dividend?

The last dividend was paid out on 6/26/2015.

What was the dividend of Austar Lifesciences in the year 2023?

In the year 2023, Austar Lifesciences distributed 0 CNY as dividends.

In which currency does Austar Lifesciences pay out the dividend?

The dividends of Austar Lifesciences are distributed in CNY.

All fundamentals about Austar Lifesciences

Our stock analysis for Austar Lifesciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Austar Lifesciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.